Bimatoprost
Sponsors
Region Vaesterbotten, Allergan, Innovative Medical, Summa Health System, University of Parma
Conditions
AlopeciaAlopecia, AndrogeneticAndrogenetic AlopeciaApplication Site Pigmentation ChangesBaldnessBurn ScarBurns LaserCicatrix
Early Phase 1
Phase 1
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
TerminatedNCT02676310
Start: 2016-03-31End: 2017-03-31Updated: 2017-03-17
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
CompletedNCT02742649
Start: 2016-04-30End: 2016-12-31Updated: 2019-02-25
Phase 2
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
CompletedNCT00300443
Start: 2005-12-31End: 2007-06-30Updated: 2011-05-30
Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT01291108
Start: 2011-04-30End: 2011-10-31Updated: 2013-11-06
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
CompletedNCT01915940
Start: 2013-10-23End: 2014-11-14Updated: 2018-04-20
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
CompletedNCT02143843
Start: 2014-06-05End: 2016-01-31Updated: 2019-02-26
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
CompletedNCT02170662
Start: 2009-11-30End: 2011-05-31Updated: 2014-09-05
Dose-Ranging Study of the Bimatoprost Ocular Insert
CompletedNCT02358369
Start: 2015-01-19End: 2015-10-07Updated: 2020-06-04
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
CompletedNCT02537015
Start: 2015-08-10End: 2016-08-11Updated: 2019-04-02
Treatment of Hypopigmented Scars With Bimatoprost
RecruitingNCT06122090
Start: 2023-07-18End: 2025-07-31Target: 25Updated: 2024-05-03
Phase 3
Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures
CompletedNCT02154217
Updated: 2014-06-03
Stop Retinal Ganglion Cell Dysfunction Study
TerminatedNCT02390284
Start: 2015-09-30End: 2024-10-04Updated: 2025-08-26
Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
CompletedNCT03825380
Start: 2018-11-23End: 2021-02-24Updated: 2023-11-21
Phase 4
A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
CompletedNCT00348062
Updated: 2007-06-01
The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
CompletedNCT00705757
Start: 2008-03-31End: 2011-04-30Updated: 2016-01-18
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
CompletedNCT01655758
Start: 2002-01-31End: 2004-02-29Updated: 2012-08-02
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
CompletedNCT02059655
Start: 2014-11-30End: 2016-03-31Updated: 2016-05-06
Glaucoma Intensity Treatment Study – Intensive non-invasive glaucoma treatment vs conventional stepwise treatment – a prospective, randomized phase IV study of disease progression in glaucoma
Active, not recruitingCTIS2023-510041-16-00
Start: 2013-04-22Target: 240Updated: 2024-05-16